Patrick Neven
Impact in
- Obstetrics and Gynecology top 0.1%
- Endometrial and Cervical Cancer Treatments
- Oncology top 0.1%
- HER2/EGFR in Cancer Research
- Cancer-related Molecular Pathways
- Bone health and treatments
Papers in
- Oncology 188
- HER2/EGFR in Cancer Research 65
- Cancer Treatment and Pharmacology 55
- Cancer Risks and Factors 30
-
- Advanced Breast Cancer Therapies 133
- Co-authors
- Ignace Vergote (107 shared papers)Frédéric Amant (88 shared papers)Philippe Moerman (26 shared papers)Erik Van Limbergen (27 shared papers)D. Timmerman (23 shared papers)Hans Wildiers (119 shared papers)Robert Paridaens (70 shared papers)Marie-Rose Christiaens (37 shared papers)
- Journals
- Cancer Research (63 papers)Journal of Clinical Oncology (60 papers)Annals of Oncology (47 papers)Breast Cancer Research and Treatment (41 papers)International Journal of Gynecological Cancer (26 papers)
- Partner nations
- BelgiumUnited StatesFrance
In The Last Decade
Patrick Neven
470 papers receiving 16.1k citations
Patrick Neven's Hit Papers
Peers
Comparison fields: 5 of 154
- Obstetrics and Gynecology 1.8k
- Oncology 6.5k
- Cancer Research 3.4k
- Reproductive Medicine 1.3k
- Pulmonary and Respiratory Medicine 4.4k
Countries citing papers authored by Patrick Neven
This map shows the geographic impact of Patrick Neven's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Patrick Neven with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Patrick Neven more than expected).
Fields of papers citing papers by Patrick Neven
This network shows the impact of papers produced by Patrick Neven. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Patrick Neven. The network helps show where Patrick Neven may publish in the future.
Co-authors
The 25 scholars most cited alongside Patrick Neven, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 501 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Endometrial cancer Hit paper breakdown → | 2005 | 1207 |
| 2 | MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2− Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy Hit paper breakdown → | 2017 | 1161 |
| 3 | The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor–Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy—MONARCH 2 Hit paper breakdown → | 2019 | 632 |
| 4 | A single-cell map of intratumoral changes during anti-PD1 treatment of patients with breast cancer Hit paper breakdown → | 2021 | 471 |
| 5 | Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2 Hit paper breakdown → | 2014 | 432 |
| 6 | 2007 | 361 | |
| 7 | 2010 | 298 | |
| 8 | 2011 | 284 | |
| 9 | 2008 | 267 | |
| 10 | 2012 | 266 | |
| 11 | 2004 | 248 | |
| 12 | 2012 | 247 | |
| 13 | Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study Hit paper breakdown → | 2021 | 236 |
| 14 | 2008 | 179 | |
| 15 | 2015 | 178 | |
| 16 | Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival Hit paper breakdown → | 2021 | 174 |
| 17 | 2012 | 174 | |
| 18 | 2016 | 171 | |
| 19 | 2015 | 146 | |
| 20 | 2016 | 146 |
About Patrick Neven
Patrick Neven is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Genetics, Cancer Research and Obstetrics and Gynecology, having authored 501 papers that have together received 16.6k indexed citations. Recurring topics across this work include Advanced Breast Cancer Therapies (133 papers), Estrogen and related hormone effects (92 papers), Breast Cancer Treatment Studies (73 papers), HER2/EGFR in Cancer Research (65 papers), Cancer Treatment and Pharmacology (55 papers), Endometrial and Cervical Cancer Treatments (31 papers), Cancer Risks and Factors (30 papers) and Ovarian cancer diagnosis and treatment (24 papers). The work is most often cited by research in Obstetrics and Gynecology (1.8k citations), Oncology (6.5k citations), Cancer Research (3.4k citations), Reproductive Medicine (1.3k citations) and Pulmonary and Respiratory Medicine (4.4k citations). Patrick Neven has collaborated with scholars based in Belgium, United States and France. Frequent co-authors include Ignace Vergote, Frédéric Amant, Philippe Moerman, Erik Van Limbergen, D. Timmerman, Hans Wildiers, Robert Paridaens, Marie-Rose Christiaens, Ann Smeets and Karin Leunen. Their work appears in journals such as Cancer Research, Journal of Clinical Oncology, Annals of Oncology, Breast Cancer Research and Treatment and International Journal of Gynecological Cancer.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.